other material
confidence high
sentiment positive
materiality 0.75
Sutro selects luvelta dose for registrational ovarian cancer trial; 32% ORR in Part 1
SUTRO BIOPHARMA, INC.
- Selected dose: 5.2 mg/kg with prophylactic pegfilgrastim for 2 cycles then 4.3 mg/kg for subsequent cycles.
- Topline Part 1 (5.2 mg/kg, N=25): ORR 32%, DCR 96%; half of patients ineligible for approved FRα-targeting ADC.
- 88% of patients received prior bevacizumab; Grade 3+ neutropenia 32%, no febrile neutropenia.
- Part 2 registrational trial to enroll ~500 patients randomized 1:1 luvelta vs investigator's choice chemo.